EMEA-002307-PIP01-17-M01

Key facts

Active substance
Monovalent, live, recombinant, replication-incompetent adenoviral serotype 26 vectored vaccine expressing the full length glycoprotein of the Ebola virus Mayinga variant [Ad26.ZEBOV]
Therapeutic area
Infectious diseases
Decision number
P/0155/2020
PIP number
EMEA-002307-PIP01-17-M01
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of Ebola virus disease
Route(s) of administration
Intramuscular use
Contact for public enquiries
Janssen Cilag International NV

Tel. +3214602111
E-mail: contact@Janssen-emea.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating